I am going to develop a model of acute resistance to the HER2 inhibitor, lapatinib, in breast cancer cells. Upon inhibition of HER2 activity, cells up-regulate the levels of several receptor tyrosine kinases. These RTKs promote survival signaling. These events will be modeled and this will be used to explain resistance.